Cagrilintide

Cagrilintide is a synthetic, long-acting peptide and an acylated analog of the hormone amylin. Developed by Novo Nordisk, it is an investigational drug, often referred to as a “peptide therapy” that acts as a dual amylin and calcitonin receptor agonist (DACRA) to manage weight by reducing appetite and slowing gastric emptying.

Key Benefits

• Supports natural growth hormone release
• May help improve muscle recovery and lean muscle support
• Commonly researched for better sleep quality and recovery
• May support fat metabolism, energy, and healthy aging

FDA-Approved Uses

Cagrilintide is not FDA-approved as a standalone product or in combination. Novo Nordisk filed an NDA for CagriSema (cagrilintide + semaglutide 2.4 mg fixed-dose combination) in December 2025. FDA decision expected October–November 2026.

Cagrilintide CANNOT be legally compounded or obtained outside of registered clinical trials. The FDA explicitly stated it cannot be used in compounding under federal law. In September 2025, the FDA sent 40+ warning letters to compounding pharmacies specifically naming cagrilintide.

Conditions under Phase 3 investigation (REDEFINE program):

• Obesity / Overweight — CagriSema combination
• REDEFINE 1: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities
• REDEFINE 2: Adults with obesity and T2DM
• REDEFINE 4: 23% mean weight loss at 84 weeks (Feb 2026 readout)
• Type 2 Diabetes (with obesity) — combination
• Cardiovascular outcomes (ongoing)

Standalone cagrilintide (separate trials):

• Produced ~10–11.8% weight loss at 68 weeks (2.4 mg/week) as monotherapy
• Used a different pathway from GLP-1 drugs — works via amylin receptors

Trade Names in the USA and Manufacturers

No approved trade name (investigational).

Developer/Manufacturer: Novo Nordisk (Copenhagen, Denmark)
Investigational product name: CagriSema (fixed-dose combination of cagrilintide 2.4 mg + semaglutide 2.4 mg)
Compound code: Cagrilintide (standalone)

Legal US access (as of May 2026):

• Clinical trial enrollment ONLY
• No compounding (FDA explicitly prohibited)
• No research chemical suppliers (enforcement action taken)
• Estimated earliest commercial availability: Late 2026 (if CagriSema approved) to 2028 (standalone)

Dosage

Cagrilintide standalone (Phase 3 trial protocol — subcutaneous weekly injection):

• Weeks 1–4: 0.16 mg/week
• Weeks 5–8: 0.25 mg/week
• Weeks 9–12: 0.5 mg/week
• Weeks 13–16: 1.0 mg/week
• Weeks 17–20: 1.7 mg/week
• Week 21+: 2.4 mg/week (maintenance)
• [16-week escalation before reaching maintenance dose; slower escalation improves tolerability]

CagriSema combination (Phase 3):
Combined fixed-dose: cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly
Titration follows the slower of the two components’ schedules

Available as lyophilized powder (5 mg and 10 mg vials from research suppliers — for research use only).

Pricing

Clinical trial enrollment: Free (supervised)
Compounding: Prohibited — no legal compounding source
Research chemical vendors: Technically available but FDA has actively warned against and sent enforcement letters

Projected commercial pricing (speculative, post-approval):
Expected to be comparable to Wegovy/Ozempic pricing given manufacturer (Novo Nordisk)
Likely $1,000–$1,400/month list price if approved (based on Novo Nordisk’s existing GLP-1 pricing structure)

Coverage by Insurance Type

Not covered by any insurance:
– ACA / Commercial / Medicare / Medicaid / TRICARE: Not applicable ❌

Note: Compounding is explicitly prohibited by FDA — no pathway exists for insurance-covered or cash-pay compounding as of May 2026.

Once approved, coverage expected to follow similar patterns as semaglutide (Wegovy), with:
– Strong coverage for T2DM indication
– Limited/variable coverage for obesity-only indication

Tips

• Only legal access to cagrilintide as of May 2026 is through registered Phase 3 clinical trials. Search ClinicalTrials.gov for ‘cagrilintide’ or ‘CagriSema’ or ‘REDEFINE’.
• Do NOT use products labeled as cagrilintide from compounding pharmacies or research chemical vendors — FDA has explicitly prohibited compounding and issued warning letters.
• Monitor Novo Nordisk’s NDA timeline; FDA decision expected October–November 2026 for CagriSema combination.
• Cagrilintide works through a completely different pathway (amylin receptors) than GLP-1 drugs — it is NOT a substitute for semaglutide or tirzepatide.
• The key advantage of CagriSema is the combination of two different appetite-suppression pathways (amylin + GLP-1) providing additive efficacy with potentially lower GI side effect burden than maximizing only one pathway.

Side Effects

Based on Phase 2 and Phase 3 REDEFINE trial data:

Common (dose-dependent):
– Nausea: Most frequently reported; rates correlate with escalation speed
– Constipation
– Diarrhea
– Vomiting
– Injection site reactions
– Extreme appetite suppression (can be clinically significant)

Less common:
– Abdominal discomfort / pain
– Fatigue
– Headache

Under active monitoring in Phase 3:
– Psychiatric effects: CNS activity monitored; no significant suicidality or severe mood disturbance in Phase 2 data, but remains an active monitoring parameter
– Gallbladder events (standard monitoring for weight loss drugs)
– Pancreatitis (standard monitoring)
– Cardiovascular events

Tolerability note: Slower dose escalation (16-week titration) significantly reduces GI event rates vs. faster escalation.

Contraindications

No formal contraindications established (no approved label).

Based on trial exclusion criteria and pharmacology:
– Active malignancy: Expected contraindication (growth factor stimulation concerns)
– Pregnancy: Excluded from all trials; expected contraindication
– Personal/family history of MTC or MEN2: Expected (due to semaglutide component in CagriSema)
– History of pancreatitis: Excluded from trials
– Severe renal or hepatic impairment: Not fully characterized
– Hypersensitivity to cagrilintide or excipients: Expected
– Compounding or off-label use: FDA explicitly prohibited

⚠️ Final contraindications to be established in the FDA-approved prescribing information if/when approved.

Pharmacology

Cagrilintide is a long-acting synthetic analogue of amylin (islet amyloid polypeptide, IAPP), a hormone co-secreted with insulin by pancreatic beta cells. Natural amylin has a plasma half-life of approximately 15 minutes, making it impractical as a therapeutic. Cagrilintide was engineered by Novo Nordisk with structural modifications that extend its half-life to 7–8 days, enabling once-weekly subcutaneous dosing. It acts through a completely different receptor system than GLP-1 agonists — making it mechanistically complementary to semaglutide and tirzepatide rather than duplicative.

Mechanism of action

Cagrilintide activates amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR) in the brainstem (area postrema) and hypothalamus — regions critical for appetite and satiety regulation.

Key effects:
1. Appetite suppression via amylin pathway (distinct from GLP-1 pathway):
– Reduces food intake by acting on hindbrain satiety centers
– Slows gastric emptying (like GLP-1, but via different mechanism)
– Reduces meal size and increases satiety duration

2. Glucose regulation:
– Suppresses post-meal glucagon secretion
– Slows carbohydrate absorption from the gut

3. Combination with semaglutide (CagriSema):
– Dual pathway activation (amylin + GLP-1 receptors simultaneously)
– Additive appetite suppression — greater than either alone
– May allow effective weight loss at lower individual doses, potentially improving tolerability

The amylin pathway is physiologically distinct from the GLP-1 pathway, targeting different neuronal circuits in the brainstem.

Result Claims from Different Companies

Novo Nordisk (based on published Phase 2 and Phase 3 trial data):

Standalone cagrilintide:
– Phase 2 (DOSE-FINDING trial): ~10–11.8% mean body weight reduction at 68 weeks with 2.4 mg/week; fewer GI side effects than semaglutide monotherapy at equivalent weight-loss doses.

CagriSema combination (Phase 3 REDEFINE program):
– REDEFINE 1: ~22.7% mean body weight reduction in adults with obesity (the highest ever reported for a near-approval combination therapy at Phase 3 as of publication).
– REDEFINE 2: Significant HbA1c reduction and ~18–20% weight loss in adults with T2DM and obesity.
– REDEFINE 4 (Feb 23, 2026 readout): 23% weight loss at 84 weeks.

⚠️ All claims are from clinical trial results and Novo Nordisk press releases. CagriSema is NOT FDA approved. No guarantee of outcomes. Compounding is explicitly prohibited by FDA.

Disclaimer

This content about “Cagrilintide” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.